DNX-2401 adenovirus: Difference between revisions
(Updated category= to treatment_category= in TreatmentInfo template) |
No edit summary |
||
| Line 13: | Line 13: | ||
with 10-1000 fold increased levels of interleukin-12p70, a cytokine with great importance | with 10-1000 fold increased levels of interleukin-12p70, a cytokine with great importance | ||
for type-1 anti-tumor immune responses. | for type-1 anti-tumor immune responses. | ||
}} | |overview=DNX-2401 is a modified adenovirus used in oncolytic virotherapy, demonstrating promising results in a phase 1 trial for recurrent high-grade glioma patients at MD Anderson, with three patients achieving complete, durable responses lasting 29 to 42 months and showing significant immune responses. Preliminary findings were presented at the November 2014 SNO conference, highlighting no adverse events related to the virus.}} | ||
Latest revision as of 01:29, 18 January 2025
| Property | Information |
|---|---|
| Drug Name | DNX-2401 adenovirus |
| Overview | DNX-2401 is a modified adenovirus used in oncolytic virotherapy, demonstrating promising results in a phase 1 trial for recurrent high-grade glioma patients at MD Anderson, with three patients achieving complete, durable responses lasting 29 to 42 months and showing significant immune responses. Preliminary findings were presented at the November 2014 SNO conference, highlighting no adverse events related to the virus. |
| FDA Approval | Not specified |
| Used for | Not specified |
| Clinical Trial Phase | Not specified |
| Clinical Trial Explanation | Not specified |
| Common Side Effects | Not specified |
| OS without | Not specified |
| OS with | Not specified |
| PFS without | Not specified |
| PFS with | Not specified |
| Usefulness Rating | Not rated |
| Usefulness Explanation | Not specified |
| Toxicity Level | Not specified |
| Toxicity Explanation | Not specified |
From Ben Williams Book: Another viral therapy in phase 1 has had impressive results, comparable to the PVS-RIPO trial. DNX-2401 is a modified adenovirus that is directly injected into the tumor. Preliminary results of a phase 1 trial at MD Anderson in Houston, Texas were presented at the November 2014 SNO conference in Miami. 37 recurrent high-grade glioma patients had been treated, with no adverse events attributable to the virus being reported. 3 of 25 patients responded to the treatment with complete, durable responses of 42, 32, and 29 months so far. These three complete responders had vigorous immune responses, with 10-1000 fold increased levels of interleukin-12p70, a cytokine with great importance for type-1 anti-tumor immune responses.Property "Has original text" (as page type) with input value "Another viral therapy in phase 1 has had impressive results, comparable to the PVS-RIPO</br>trial. DNX-2401 is a modified adenovirus that is directly injected into the tumor.</br>Preliminary results of a phase 1 trial at MD Anderson in Houston, Texas were presented</br>at the November 2014 SNO conference in Miami. 37 recurrent high-grade glioma</br>patients had been treated, with no adverse events attributable to the virus being reported.</br>3 of 25 patients responded to the treatment with complete, durable responses of 42, 32,</br>and 29 months so far. These three complete responders had vigorous immune responses,</br>with 10-1000 fold increased levels of interleukin-12p70, a cytokine with great importance</br>for type-1 anti-tumor immune responses." contains invalid characters or is incomplete and therefore can cause unexpected results during a query or annotation process.
